Protalix BioTherapeutics (PLX) Shares Outstanding (Weighted Average) (2010 - 2026)

Protalix BioTherapeutics has reported Shares Outstanding (Weighted Average) for 17 years, with the latest figure at $79.8 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 4.23% year-over-year to $79.8 million; the trailing twelve-month figure through Mar 2026 stood at $79.8 million (up 4.23% YoY), and the FY2025 full-year result was $78.5 million, up 8.29% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $79.8 million, up from $78.5 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $79.8 million in Q1 2026, with the low at $45.8 million in Q1 2022.
• Average Shares Outstanding (Weighted Average) over 5 years is $66.3 million, with a median of $72.5 million recorded in 2024.
• Year-over-year, Shares Outstanding (Weighted Average) increased 4.16% in 2022 and jumped 39.28% in 2023.
• Tracing PLX's Shares Outstanding (Weighted Average) over 5 years: stood at $48.5 million in 2022, then jumped by 39.28% to $67.5 million in 2023, then increased by 7.43% to $72.5 million in 2024, then gained by 8.29% to $78.5 million in 2025, then increased by 1.66% to $79.8 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $79.8 million (Q1 2026), $78.5 million (Q4 2025), and $78.2 million (Q3 2025), per Business Quant data.

Peer Comparison